I am preparing to conduct in vivo animal studies with Ostamatinib (Cat. No. HY-13038A), administered via intraperitoneal injection. I have identified three different dissolution protocols using various solubilizing agents:
Could anyone provide insights on which of these protocols is most effective or offers the best solubility and stability for intraperitoneal administration? Your expertise would be greatly appreciated!
When solubility requirements are met, Protocols 1 and 2 are recommended as the first choices, with the cosolvent used in Protocol 2 being relatively more costly. The corn oil-based protocol is generally not prioritized, primarily due to concerns regarding mouse tolerance—its administration may potentially lead to issues with drug absorption in mice.
A critical consideration across all protocols is the toxicity of DMSO. For normal mice, a 10% DMSO concentration is well-tolerated. However, for mice with compromised health status, such as those with immunodeficiency, gene knockout, or other debilitating conditions, it is strongly advisable to reduce the DMSO concentration to 2%.
The answer to this question is provided by MedChemExpress Technical Support.
- Badges
- Science method